| Literature DB >> 21603151 |
Jorge Lamarche1, Reji Nair, Alfredo Peguero, Craig Courville.
Abstract
Although a multitude of syndromes have been thoroughly described as a result of vitamin deficiencies, over consumption of such substances may also be quite dangerous. Intratubular crystallization of calcium oxalate as a result of hyperoxaluria can cause acute renal failure. This type of renal failure is known as oxalate nephropathy. Hyperoxaluria occurs as a result of inherited enzymatic deficiencies known as primary hyperoxaluria or from exogenous sources known as secondary hyperoxaluria. Extensive literature has reported and explained the mechanism of increased absorption of oxalate in malabsorptive syndromes leading to renal injury. However, other causes of secondary hyperoxaluria may also take place either via direct dietary consumption of oxalate rich products or via other substances which may metabolize into oxalate within the body. Vitamin C is metabolized to oxalate. Oral or parenteral administration of this vitamin has been used in multiple settings such as an alternative treatment of malignancy or as an immune booster. This article presents a clinical case in which ingestion of high amounts of vitamin C lead to oxalate nephropathy. This article further reviews other previously published cases in order to illustrate and highlight the potential renal harm this vitamin poses if consumed in excessive amounts.Entities:
Year: 2011 PMID: 21603151 PMCID: PMC3096888 DOI: 10.4061/2011/146927
Source DB: PubMed Journal: Int J Nephrol
Figure 1(a) shows renal cortex with acute tubular injury. (b) depicts the same area under polarized light. The arrows indicate the deposition of calcium oxalate crystals. H&E, ×200.
Summary of biopsy proven cases of oxalate nephropathy secondary to ascorbic acid reported in the literature.
| Patient (Ref. Num.)* | Age | Gender | Baseline Serum creatinine (mg/dl) | Renal presentation and serum creatinine (Cr) in mg/dl | Dose of ascorbic acid per day | Duration of administration | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|
| 20 | 71 | Female | 1.4 | Anuria (Cr = 12.1) | 500 mg (oral) | 6 months | HD | ESRD |
| 15** | 58 | Female | 1.0 | Oliguria (Cr = 3.5 ) | 45 g (IV) | 1 day | HD | Death |
| 21*** | 72 | Male | Unknown | Anuria(Cr = 15.3) | Grams (oral) | Months | Medical | Death |
| 22 | 73 | Male | 1.2 | Poor renal clearance | 680 mg (oral) | 4 months | HD | Recovery |
| 23 | 31 | Male | Unknown | Poor renal clearance | 2.5–5.0g (oral) | Undisclosed (week to months?) | HD | Recovery |
| 24 | 49 | Female | 0.7 | Oliguria (Cr = 4.5) | 4.0 g (oral) | Several months | HD | Recovery |
| 10 | 58 | Male | 1.4 | Anuria (undisclosed) | 1 g (IV) | 2 months | HD | Recovery |
| 14 | 61 | Male | 1.3 | Anuria (Cr = 13.3) | 60 g (IV) | 1 day | Medical | Recovery |
*The ref. num. identifies the individual case report. Please refer to the listed references at the end of the article to locate any particular case report by its reference number.
**The patient died from multiple organ failure. Her systemic illness was amyloidosis.
***The patient died from renal failure and associated multiple organ failure as he did not want to undergo dialysis.